There are insufficient historical data to establish the magnitude of drug effect for antibacterial drugs compared with placebo at a TOC time point.
FOCUS=Ceftaroline Community-Acquired Pneumonia Trial vs Ceftriaxone in Hospital Patients. FOCUS 1=CABP Trial 1, FOCUS 2=CABP Trial 2.
Clinical efficacy of TEFLARO in treating CABP due to MRSA has not been studied.
Proven efficacy at TOC against the most common pathogens in CABP1 | ||
Pooled clinical cure rates in ME patients, % (n/N) | ||
Pathogen | TEFLARO | Ceftriaxone |
Gram-positive | ||
S. pneumoniae | 85.7 (54/63) | 69.5 (41/59) |
S. aureus (MSSA only‡) | 72.0 (18/25) | 56.0 (14/25) |
Gram-negative | ||
H. influenzae | 83.3 (15/18) | 85.0 (17/20) |
K. pneumoniae | 100.0 (12/12) | 83.3 (10/12) |
K. oxytoca | 83.3 (5/6) | 87.5 (7/8) |
E. coli | 83.3 (10/12) | 75.0 (9/12) |
Proven efficacy at TOC against the most common pathogens in CABP1 | ||
Pooled clinical cure rates in ME patients, % (n/N) | ||
TEFLARO | Ceftriaxone | |
Pathogen | ||
Gram-positive | ||
S. pneumoniae | ||
85.7 (54/63) | 69.5 (41/59) | |
S. aureus (MSSA only‡) | ||
72.0 (18/25) | 56.0 (14/25) | |
Gram-negative | ||
H. influenzae | ||
83.3 (15/18) | 85.0 (17/20) | |
K. pneumoniae | ||
100.0 (12/12) | 83.3 (10/12) | |
K. oxytoca | ||
83.3 (5/6) | 87.5 (7/8) | |
E. coli | ||
83.3 (10/12) | 75.0 (9/12) |
There are insufficient historical data to establish the magnitude of drug effect for antibacterial drugs compared with placebo at a TOC time point.
MSSA=Methicillin-susceptible Staphylococcus aureus.
Clinical efficacy of TEFLARO in treating CABP due to MRSA has not been studied.
These hypothetical case studies present examples of types of patients who may benefit from TEFLARO.
Please also see full Prescribing Information.
Please also see full Prescribing Information.